Advertisement
Advertisement
NRIX
Nurix Therapeutics, Inc. Common stock
16.85
USDSponsored
+0.90
+5.62%
Feb 06, 15:59 UTC -5
Closed
After-Market
16.84
0.00
-0.01%
NRIX Earnings Reports
Positive Surprise Ratio
NRIX beat 10 of 22 last estimates.
45%
Next Report
Date of Next Report
Apr 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.28M
/-$0.78
Implied change from Q4 25 (Revenue/ EPS)
+19.88%
/-4.88%
Implied change from Q1 25 (Revenue/ EPS)
-11.80%
/+16.42%
Nurix Therapeutics, Inc. Common stock earnings per share and revenue
On Jan 28, 2026, NRIX reported earnings of -0.82 USD per share (EPS) for Q4 25, beating the estimate of -0.88 USD, resulting in a 7.66% surprise. Revenue reached 13.58 million, compared to an expected 14.60 million, with a -6.98% difference. The market reacted with a +3.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.78 USD, with revenue projected to reach 16.28 million USD, implying an decrease of -4.88% EPS, and increase of 19.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Nurix Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Nurix Therapeutics, Inc. Common stock reported EPS of -$0.82, beating estimates by 7.66%, and revenue of $13.58M, -6.98% below expectations.
How did the market react to Nurix Therapeutics, Inc. Common stock's Q4 2025 earnings?
The stock price moved up 3.52%, changed from $18.75 before the earnings release to $19.41 the day after.
When is Nurix Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for Apr 06, 2026.
What are the forecasts for Nurix Therapeutics, Inc. Common stock's next earnings report?
Based on 10
analysts, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.78 and revenue of $16.28M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement